News Details
NCCN and CancerLinQ Collaborating to Provide Evidence-Based, Decision-Making Resources to Physicians
New Collaboration Will Grant CancerLinQ Subscribers Streamlined Access to the NCCN Compendium®
[FORT WASHINGTON, PA — May 31, 2017] The National Comprehensive Cancer Network® (NCCN®) and CancerLinQ LLC, a wholly owned nonprofit subsidiary of the American Society of Clinical Oncology (ASCO), announced today a collaboration to provide a link to the NCCN Website for easy access to the NCCN Drugs & Biologics Compendium (NCCN Compendium®) within CancerLinQ®, a big data platform aimed at improving quality of care for patients with cancer. This resource will support CancerLinQ physicians and provides evidence-based guidance regarding the appropriate use of drugs and biologics in patients with cancer.
“We are pleased to collaborate with ASCO and CancerLinQ to support clinician access to evidence-based resources through technology at the point of care,” said Robert W. Carlson, MD, Chief Executive Officer, NCCN. “Based directly on the NCCN Guidelines, the Compendium will benefit CancerLinQ users by providing authoritative, scientifically derived information designed to support decision-making about the appropriate use of drugs and biologics in patients with cancer.”
With this collaboration, CancerLinQ subscribers will now have access to a link that will bring them directly to the NCCN Compendium®, where they can subscribe, for a fee. NCCN is able to make available its resources to the growing CancerLinQ network, which includes thousands of oncologists treating millions of patients from a variety of practice types and institutions across the United States. This collaboration represents one of the ways in which NCCN is empowering physicians to access NCCN resources through everyday health information technology (HIT) workflow.
“CancerLinQ exists in service to our members to improve quality,” said Kevin Fitzpatrick, Chief Executive Officer, CancerLinQ LLC. “As we continue to convene collaborators across the oncology community, we encourage efforts that enable resources to be more easily accessible for providers to make informed and timely decisions in the delivery of care to their patients. This collaboration is just one more positive step in that direction.”
The NCCN Compendium contains recommendations for the appropriate use of drugs and biologics to support decision-making for patients with cancer. The recommendations are derived directly from relevant NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), along with their clinical context, route of administration, recommended use, and NCCN category of evidence. In addition to NCCN Guidelines-specific indication and use, NCCN adds relevant information, such as pharmacologic class, relevant classification codes, and U.S. Food and Drug Administration (FDA) indication, to the searchable database. All information is reviewed by members of the relevant NCCN Guidelines® panel before publication.
The CancerLinQ platform is a big data initiative focused on cancer patient medical information, aimed at improving the quality of patient care and outcomes. It is the only major cancer data initiative being developed and led by physicians. When complete, CancerLinQ will unlock real-world patient care data from millions of electronic health records and securely process and analyze the data to provide immediate quality feedback and clinical decision support to providers. Doctors will receive personalized insights on a scope that was previously unattainable, and patients will benefit by having access to high quality care based on up-to-date insights and findings.
The NCCN Guidelines are the recognized standard for clinical policy in cancer care and are the most thorough and most frequently updated clinical practice guidelines available in any area of medicine. For more information, visit NCCN.org.
###
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 27 leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers.
The NCCN Member Institutions are: Fred & Pamela Buffett Cancer Center, Omaha, NE; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; City of Hope Comprehensive Cancer Center, Los Angeles, CA; Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center, Boston, MA; Duke Cancer Institute, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Mayo Clinic Cancer Center, Phoenix/Scottsdale, AZ, Jacksonville, FL, and Rochester, MN; Memorial Sloan Kettering Cancer Center, New York, NY; Moffitt Cancer Center, Tampa, FL; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH; Roswell Park Cancer Institute, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center, Memphis, TN; Stanford Cancer Institute, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UC San Diego Moores Cancer Center, La Jolla, CA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Colorado Cancer Center, Aurora, CO; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; The University of Texas MD Anderson Cancer Center, Houston, TX; University of Wisconsin Carbone Cancer Center, Madison, WI; Vanderbilt-Ingram Cancer Center, Nashville, TN; and Yale Cancer Center/Smilow Cancer Hospital, New Haven, CT.
Clinicians, visit NCCN.org. Patients and caregivers, visit NCCN.org/patients. Media, visit NCCN.org/news.
About ASCO
Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. As the world’s leading organization of its kind, ASCO represents more than 40,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of the highest-quality patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation. Learn more at www.ASCO.org, explore patient education resources at www.Cancer.Net, and follow us on Facebook, Twitter, LinkedIn, and YouTube.
About CancerLinQ LLC
CancerLinQ LLC is a subsidiary of American Society of Clinical Oncology, Inc. established for the development and operation of the CancerLinQ® initiative. CancerLinQ is a health information technology platform aimed at enhancing and improving the understanding and treatment of cancer. To learn more, visit www.cancerlinq.org.